Actively Recruiting

Age: 18Years +
All Genders
NCT05766449

Risk Factors for Hepatic Inflammation, Fibrosis and Prognosis in Patients With CHB and NAFLD

Led by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Updated on 2023-03-13

1000

Participants Needed

1

Research Sites

256 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Chronic hepatitis B (CHB) affects an estimated 292 million people, and causes approximately 800,000 people deaths per year from liver-related complications including cirrhosis and hepatocellular carcinoma, remaining a major global public health issue.Meanwhile, with the improvement of living standards and changes in lifestyle and dietary habits, non-alcoholic fatty liver disease (NAFLD) has become another important cause of liver cirrhosis and HCC.HBV combined with NAFLD inevitably develops into continuous or intermittent liver inflammation and fibrosis, which greatly increases the risk of cirrhosis, liver cancer and even end-stage liver disease. We aimed to investigate the risk factors and establish diagnostic models for hepatic inflammation, fibrosis in patients with CHB associated NAFLD. In addition, to find risk factors for liver cirrhosis, liver cancer or liver failure in patients with CHB-related NAFLD.

CONDITIONS

Official Title

Risk Factors for Hepatic Inflammation, Fibrosis and Prognosis in Patients With CHB and NAFLD

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 years or older
  • Positive hepatitis B surface antigen (HBsAg) for at least 6 months without other viral co-infection at baseline
  • Non-alcoholic fatty liver disease (NAFLD) diagnosed by imaging, liver biopsy, and/or blood testing or predictive indices
Not Eligible

You will not qualify if you...

  • Presence of other chronic liver diseases such as alcoholic liver disease, other viral hepatitis, or drug-induced liver injury
  • Diagnosis of hepatocellular carcinoma (HCC) or other malignancies before liver biopsy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Nanjing Drum Tower Hospital

Nanjing, China

Actively Recruiting

Loading map...

Research Team

J

Jie Li, M.D., Ph.D

CONTACT

F

Fajuan Rui

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here